GOTHENBURG, Sweden, April 27 /CNW/ - Cellectricon, a leading provider of
automated screening solutions for drug discovery, today announced its
collaboration with BioFocus DPI, a contract research organization with leading
expertise in ion channel screening. BioFocus DPI will utilize Cellectricon's
Dynaflow(R)HT, a fully automated patch clamp (APC) system, to further increase
its electrophysiology-based screening capacity, particularly for fast
ligand-gated ion channels.
"Cellectricon's unique high throughput microfluidic screening platform
allows us to further develop our leading platform for ion channel screening.
This collaboration gives us the opportunity to increase the throughput we
provide for customers as well as the number of ion channel subtypes we can
screen in an electrophysiology-based format," said Dr. Kate Hilyard, VP
Biological Sciences, BioFocus DPI.
"Cellectricon is very pleased to provide BioFocus DPI with this
state-of-the-art enabling technology that enhances their ion channel drug
discovery offering," said Jonas Ohlsson, CEO at Cellectricon. "BioFocus DPI is
a leading service provider in this field, so it is natural that we collaborate
on this new high throughput ion channel screening system. We are delighted to
join forces with BioFocus DPI to bring this next generation APC system - with
unmatched throughput and data quality at a competitive cost - to the market."
About Dynaflow(R)HT System
The Dynaflow(R)HT microfluidic ion channel screening platform is the
world's first APC technology enabling high throughput screening of all kinds
of ion channels - voltage gated or ligand gated. Fully automated, the
Dynaflow(R)HT has a throughput exceeding all existing APC systems - at a very
competitive running cost. Rapid compound exchange enables highly complex
perfusion protocols, gives superior data quality, and reduces compound usage.
The new Dynaflow(R)HT screening platform is developed in close collaboration
with leaders in the pharmaceutical industry.
Cellectricon AB, a Swedish biotech company, successfully provides
groundbreaking products to the pharmaceutical and biotechnology industries.
The company utilizes state-of-the-art interfaces to biological systems by
employing novel microfluidic technologies. This enables completely new types
of assays and devices with superior performance characteristics and
robustness. Cellectricon's products address critical bottlenecks in the drug
discovery process and have been adopted by top-reference customers, including
nine of the top ten pharmaceutical companies. In 2007, the company increased
its annual revenue by almost 50%. In 2008-2009 the company is launching two
pioneering large-scale screening platforms developed in close collaboration
with leaders in the pharmaceutical industry. Used in pre-clinical
pharmaceutical development, the Cellaxess(R)HT System enables high throughput
RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug
For further information:
For further information: Jonas Ohlsson, CEO, Phone: +46(0)709-73-47-92,
E-mail: email@example.com; Susanne Fagerlund, VP Marketing &
Communications, Phone: +46(0)31-760-35-15, E-mail: